home / stock / ikna / ikna short
Short Information | Ikena Oncology Inc. (NASDAQ:IKNA)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 642,115 |
Total Actual Volume | 7,450,931 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 32,106 |
Average Short Percentage | 14.09% |
Is there a IKNA Short Squeeze or Breakout about to happen?
See the IKNA Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-03-2024 | $1.63 | $1.63 | $1.65 | $1.62 | 76,599 | 13,431 | 17.53% |
07-02-2024 | $1.65 | $1.63 | $1.65 | $1.61 | 204,536 | 25,602 | 12.52% |
07-01-2024 | $1.61 | $1.65 | $1.69 | $1.6 | 316,167 | 32,101 | 10.15% |
06-28-2024 | $1.74 | $1.65 | $1.78 | $1.65 | 3,384,365 | 78,317 | 2.31% |
06-27-2024 | $1.65 | $1.75 | $1.78 | $1.64 | 280,432 | 57,997 | 20.68% |
06-26-2024 | $1.67 | $1.64 | $1.71 | $1.6 | 269,701 | 32,307 | 11.98% |
06-25-2024 | $1.66 | $1.68 | $1.68 | $1.6594 | 241,960 | 15,045 | 6.22% |
06-24-2024 | $1.69 | $1.68 | $1.7 | $1.675 | 200,058 | 28,965 | 14.48% |
06-21-2024 | $1.68 | $1.72 | $1.73 | $1.65 | 339,576 | 49,978 | 14.72% |
06-20-2024 | $1.69 | $1.66 | $1.69 | $1.63 | 281,963 | 35,865 | 12.72% |
06-18-2024 | $1.76 | $1.7 | $1.76 | $1.69 | 216,712 | 25,307 | 11.68% |
06-17-2024 | $1.75 | $1.74 | $1.76 | $1.69 | 165,200 | 29,751 | 18.01% |
06-14-2024 | $1.74 | $1.75 | $1.76 | $1.72 | 147,449 | 31,530 | 21.38% |
06-13-2024 | $1.76 | $1.77 | $1.77 | $1.72 | 144,406 | 29,146 | 20.18% |
06-12-2024 | $1.86 | $1.75 | $1.89 | $1.71 | 192,840 | 34,430 | 17.85% |
06-11-2024 | $1.75 | $1.81 | $1.82 | $1.71 | 298,229 | 22,286 | 7.47% |
06-10-2024 | $1.75 | $1.77 | $1.78 | $1.72 | 152,130 | 24,560 | 16.14% |
06-07-2024 | $1.73 | $1.75 | $1.76 | $1.71 | 137,822 | 24,150 | 17.52% |
06-06-2024 | $1.795 | $1.76 | $1.795 | $1.74 | 113,734 | 19,436 | 17.09% |
06-05-2024 | $1.75 | $1.82 | $1.85 | $1.65 | 287,052 | 31,911 | 11.12% |
News, Short Squeeze, Breakout and More Instantly...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, In...